Mallory Kathryn Ellingson, MPH
About
Research
Publications
2025
Clinical effectiveness of HPV vaccine by age at vaccination: a matched case-control study
Oliveira C, Shapiro E, Sheth S, Ellingson M, Johnson N, Sullivan E, Querec T, Unger E, Niccolai L. Clinical effectiveness of HPV vaccine by age at vaccination: a matched case-control study. The Lancet Regional Health - Americas 2025, 51: 101225. PMID: 41019517, PMCID: PMC12465035, DOI: 10.1016/j.lana.2025.101225.Peer-Reviewed Original ResearchHPV vaccinationCase-control studyHuman papillomavirusVaccine effectivenessClinical effectsDose of HPV vaccineHigh-grade cervical lesionsOdds ratioBenefits of HPV vaccinationEffectiveness of HPV vaccinationMultivariable conditional logistic regression modelsVaccine-eligible womenPap smear resultsHuman papillomavirus vaccineConfidence intervalsConditional logistic regression modelsCenters for Disease Control and PreventionDisease Control and PreventionCervical lesionsSmear resultsFirst doseHPV-16Pap testControl and PreventionLogistic regression modelsInfluence of Community-Level Factors on Health Care Provider Recommendations for HPV Vaccine
Ellingson M, O’Leary S, Schwartz J, Niccolai L. Influence of Community-Level Factors on Health Care Provider Recommendations for HPV Vaccine. Pediatrics Open Science 2025, 1: 1-9. DOI: 10.1542/pedsos.2024-000263.Peer-Reviewed Original ResearchCommunity-level factorsHealth care providersHealth care provider recommendationHuman papillomavirus vaccineHuman papillomavirusInfluence of community-level factorsNon-White adolescentsZip codesNational Immunization Survey-TeenHuman papillomavirus vaccine coverageHigh-poverty zip codesRate of unemploymentAssociated with higher population densityCommunity-level educationUS Census Bureau dataAge-eligible patientsCare provider recommendationEvidence-based interventionsCensus Bureau dataPoverty statusLogistic regression analysisAdolescent raceStatistically significant interactionCare providersSurvey-Teen
2023
Potential Impact of Higher-Valency Pneumococcal Conjugate Vaccines Among Adults in Different Localities in Germany
Ellingson M, Weinberger D, van der Linden M, Perniciaro S. Potential Impact of Higher-Valency Pneumococcal Conjugate Vaccines Among Adults in Different Localities in Germany. Journal Of Infectious Diseases 2023, 229: 1669-1673. PMID: 38059558, PMCID: PMC11175678, DOI: 10.1093/infdis/jiad538.Peer-Reviewed Original ResearchHuman papillomavirus vaccine effectiveness by age at vaccination: A systematic review
Ellingson M, Sheikha H, Nyhan K, Oliveira C, Niccolai L. Human papillomavirus vaccine effectiveness by age at vaccination: A systematic review. Human Vaccines & Immunotherapeutics 2023, 19: 2239085. PMID: 37529935, PMCID: PMC10399474, DOI: 10.1080/21645515.2023.2239085.Peer-Reviewed Original ResearchConceptsVaccine effectivenessSystematic reviewHuman Papillomavirus Vaccine EffectivenessVaccine-type HPV infectionYounger ageHigh vaccine effectivenessHuman papillomavirus vaccineVaccine effectiveness studiesYounger age groupsAdolescents ages 15Adolescents ages 9HPV infectionHPV vaccineVaccine initiationPapillomavirus vaccineTime vaccinationAnogenital wartsCervical abnormalitiesCervical cancerDisease outcomeAge groupsOlder ageEffectiveness studiesAge 15Age
2022
Understanding the Factors Influencing Health Care Provider Recommendations about Adolescent Vaccines: A Proposed Framework
Ellingson MK, Bednarczyk RA, O’Leary S, Schwartz JL, Shapiro ED, Niccolai LM. Understanding the Factors Influencing Health Care Provider Recommendations about Adolescent Vaccines: A Proposed Framework. Journal Of Behavioral Medicine 2022, 46: 356-365. PMID: 35194726, PMCID: PMC8862696, DOI: 10.1007/s10865-022-00296-4.Peer-Reviewed Original ResearchState Laws Permitting Adolescent Consent to Human Papillomavirus Vaccination and Rates of Immunization
Torres AR, Johnson NP, Ellingson MK, Hansen CE, Oliveira CR, Niccolai LM, Sheth SS. State Laws Permitting Adolescent Consent to Human Papillomavirus Vaccination and Rates of Immunization. JAMA Pediatrics 2022, 176: 203-205. PMID: 34779839, PMCID: PMC8593826, DOI: 10.1001/jamapediatrics.2021.4591.Peer-Reviewed Original Research
2021
Strategies to increase uptake of maternal pertussis vaccination
Patel KM, Guillamet L, Pischel L, Ellingson MK, Bardají A, Omer SB. Strategies to increase uptake of maternal pertussis vaccination. Expert Review Of Vaccines 2021, 20: 779-796. PMID: 34129416, PMCID: PMC9288655, DOI: 10.1080/14760584.2021.1940146.Peer-Reviewed Original ResearchConceptsMaternal pertussis vaccinationPertussis vaccinationInteractive patient educationContagious respiratory diseaseLack of studiesMaternal uptakePostpartum vaccinationPrenatal vaccinationSite vaccinationVaccine seriesMiddle-income countriesPertussis vaccineVaccine uptakePregnant womenProvider educationDisproportionate morbidityPatient educationSuboptimal uptakeVaccine communicationRespiratory diseaseVaccinationHome birthSystematic reviewDifferent interventionsInfantsPatterns of recommended vaccine receipt among women ages 24–45 years: a cross-sectional analysis
Ellingson MK, Oliveira CR, Sheth SS, Sullivan EL, Torres A, Shapiro ED, Niccolai LM. Patterns of recommended vaccine receipt among women ages 24–45 years: a cross-sectional analysis. BMC Public Health 2021, 21: 1283. PMID: 34193100, PMCID: PMC8247221, DOI: 10.1186/s12889-021-11340-4.Peer-Reviewed Original ResearchConceptsMid-adult womenVaccine receiptCross-sectional analysisHPV vaccineOngoing case-control studyReceipt of influenzaHealth care visitsCase-control studyWomen ages 24Quarter of adultsLogistic regression analysisCare visitsIndividual vaccinesHealthcare utilizationMultiple vaccinesVaccineAge 24White womenWomenDemographic characteristicsRegression analysisLower ratesInfluenzaReceiptPast yearPublishing at any cost: a cross-sectional study of the amount that medical researchers spend on open access publishing each year
Ellingson MK, Shi X, Skydel JJ, Nyhan K, Lehman R, Ross JS, Wallach JD. Publishing at any cost: a cross-sectional study of the amount that medical researchers spend on open access publishing each year. BMJ Open 2021, 11: e047107. PMID: 33526505, PMCID: PMC7852964, DOI: 10.1136/bmjopen-2020-047107.Peer-Reviewed Original Research
2020
Sex differences in immune responses that underlie COVID-19 disease outcomes
Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, Silva J, Mao T, Oh JE, Tokuyama M, Lu P, Venkataraman A, Park A, Liu F, Meir A, Sun J, Wang EY, Casanovas-Massana A, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore AJ, Shaw A, Fournier J, Odio C, Farhadian S, Dela Cruz C, Grubaugh N, Schulz W, Ring A, Ko A, Omer S, Iwasaki A. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 2020, 588: 315-320. PMID: 32846427, PMCID: PMC7725931, DOI: 10.1038/s41586-020-2700-3.Peer-Reviewed Original ResearchConceptsInnate immune cytokinesFemale patientsMale patientsImmune cytokinesDisease outcomeImmune responseCOVID-19COVID-19 disease outcomesPoor T cell responsesSARS-CoV-2 infectionSevere acute respiratory syndrome coronavirusAcute respiratory syndrome coronavirusSex-based approachModerate COVID-19Sex differencesRobust T cell activationT cell responsesWorse disease progressionWorse disease outcomesHigher plasma levelsNon-classical monocytesCoronavirus disease 2019T cell activationImmunomodulatory medicationsPlasma cytokines